Wall Street Zen Upgrades Obsidian Therapeutics (NASDAQ:OBX) to “Hold”

Obsidian Therapeutics (NASDAQ:OBX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

Other research analysts have also recently issued reports about the stock. William Blair raised shares of Obsidian Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Leerink Partners began coverage on Obsidian Therapeutics in a report on Tuesday, September 22nd. They set an “outperform” rating and a $32.00 price objective for the company. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. TD Cowen began coverage on Obsidian Therapeutics in a research report on Thursday, August 6th. They issued a “buy” rating on the stock. Finally, Lifesci Capital started coverage on Obsidian Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $43.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Obsidian Therapeutics Stock Down 0.9%

Obsidian Therapeutics stock opened at $13.86 on Friday. Obsidian Therapeutics has a 1-year low of $11.52 and a 1-year high of $49.97. The company has a fifty day simple moving average of $15.76.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.